Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and ...

Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, ...

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato ...

Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that ...

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against ...

Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially ...

At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.

Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company." ...

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success ...